Drug intelligence / Profile preview

AEX-3

Development stage: Preclinical
Lead developer: Aexon Labs
Modality: Small Molecules
Administration: Oral

Overview

AEX-3 is a small molecule orexin receptor 2 (OX2R) agonist being developed by Aexon Labs for the treatment of Narcolepsy Type 1 (NT1). Narcolepsy Type 1 is a chronic neurological disorder caused by the loss of orexin-producing neurons in the hypothalamus, resulting in symptoms such as excessive daytime sleepiness and cataplexy. AEX-3 is designed to mimic the action of endogenous orexin at the OX2R, thereby restoring wakefulness-promoting signaling and stabilizing sleep-wake cycles. As of the latest pipeline updates, the compound is in the lead generation stage of preclinical development.

Targets

HCRTR2 (Orexin/hypocretin receptor type 2)

Beyond the preview

Go deeper on AEX-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AEX-3.

Explore the full profile